PsyBio Therapeutics Corp. (PSYBF) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

PsyBio Therapeutics Corp.

PSYBF

PNK

Unprofitable

EPS improving

Unprofitable

EPS improving

303442

Biotechnology

0.01USD

0.00 ( 0.00%)

Market Open

Relative Strenght

Volume Buzz

726%

Earning Acce

Yes

Dist 52w H.

100%

Quote Panel

Updated October 24, 2024

1W 0.00 % 1M 4900.00 % 3M 4900.00 % 1Y -33.33 %

Key Metrics

Market Cap
303442
Shares Outstanding
60.68M
Share in Float
56.89M
Dividende
0

Earning Date
No Data
Price Target
0.005
Average Volume
370
Beta
0.661

Range
1.0E-4-0.021
Industry
Biotechnology
Website
https://www.psybiolife.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

-0.35x

P/B Ratio

-0.1

Debt/Equity

0.0%

Net Margin

$-0.0

EPS

How PSYBF compares to sector?

P/E Ratio

Relative Strength

PSYBF

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

No Data Available

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q1.21

N/A

NA
vs NA

Q2.21

N/A

-0.04
vs NA

Q3.21

N/A

-0.02
vs NA

Q4.21

N/A

NA
vs -0.00

Q1.22

N/A

-0.01
vs NA

Q2.22

N/A

-0.01
vs -0.04

Q3.22

N/A

-0.01
vs -0.02

Q4.22

N/A

-0.02
vs NA

Q1.23

N/A

-0.01
vs -0.01

Q2.23

N/A

-0.00
vs -0.01

Sales Growth

YoY

Current

Estimates

Q1.21

NA

NA vs NA

Q2.21

NA

NA vs NA

Q3.21

NA

NA vs NA

Q4.21

NA

NA vs NA

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Return on Equity

QoQ

Q3.21

-48%

-0.48
vs -0.59

Q4.21

-90%

-0.90
vs -0.48

Q1.22

-113%

-1.13
vs -0.90

Q2.22

-4863%

-48.63
vs -1.13

Q3.22

+114%

1.14
vs -48.63

Q4.22

+59%

0.59
vs 1.14

Q1.23

+49%

0.49
vs 0.59

Q2.23

+11%

0.11
vs 0.49

Institutionnal Ownership

Earnings Growth

Latest News

PSYBF

newsfilecorp.com

8 hours ago

PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale

PSYBF

proactiveinvestors.com

8 hours ago

PsyBio Therapeutics successfully completes first pre-IND meeting with the FDA

PSYBF

proactiveinvestors.com

9 hours ago

PsyBio Therapeutics presents 16 scientific abstracts highlighting its research and development efforts at two scientific conferences

PSYBF

proactiveinvestors.com

9 hours ago

PsyBio Therapeutics shares updates on intellectual property and clinical development milestones

PSYBF

proactiveinvestors.com

10 hours ago

PsyBio Therapeutics announces expansion of its intellectual property portfolio by filing six additional patent applications

PSYBF

proactiveinvestors.com

15 hours ago

PsyBio Therapeutics is developing psychoactive compounds which could be a mental health game changer

New Feature Coming Soon, Stay Tuned!

Shape

Shape